Two anti-inflammatory drugs reduce deaths in severe COVID-19 patients

Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis. William G. Powderly, MD, (right) who led the large clinical trial, discusses patient conditions with Maanasi Samant, MD, in the intensive care unit at Barnes-Jewish Hospital, one of the major trial sites, during the COVID-19 pandemic.

Related Keywords

United States ,America ,Williamg Powderly ,J William Campbell ,Danielle Ellis ,Maanasi Samant ,Administration For Strategic Preparedness ,Development Authority ,Us Department Of Health ,National Institutes Of Health ,National Center ,Translational Science Awards Program ,Translational Sciences ,Biomedical Advanced Research ,Washington University School Of Medicine ,Human Services ,Washington University School ,Barnes Jewish Hospital ,Strategic Preparedness ,Advancing Translational Sciences ,National Institutes ,Campbell Professor ,Infectious Diseases ,Covid 19 ,Drugs ,Abatacept ,Anti Inflammatory ,Arthritis ,Clinical Trial ,Health And Human Services ,Hospital ,Infliximab ,Intensive Care ,Medicine ,Ortality ,Pandemic ,Placebo ,Pneumonia ,Psoriasis ,Remdesivir ,Research ,Rheumatoid Arthritis ,